Safety

FDA-Approved for More Than a Decade

CIMZIA has a history of clinical use—studied in over 60 clinical trials across all approved indications.* See information about serious side effects and common side effects below.

*Includes approved indications for RA, CD, PsA, AS, PSO, pJIA, and nr-axSpA as well as other completed and ongoing research.

Known safety in Crohn’s disease treatment since 2008

During clinical studies for CIMZIA in Crohn‘s disease, the most common side effects were:

  • Upper respiratory infections in 20% of CIMZIA-treated patients vs 13% of placebo patients
  • Urinary tract infections in 7% of CIMZIA-treated patients vs 6% of placebo patients
  • Joint pain in 6% of CIMZIA-treated patients vs 4% of placebo patients

These side effects were most commonly seen during the CIMZIA controlled clinical trials in Crohn’s disease. These are not all the possible side effects that may happen with CIMZIA use. Always discuss the risks versus benefits of therapy with your doctor, and be sure to mention any side effects you experience.

View more information about side effects

Expand All

Risk of serious side effects
 

CIMZIA is an anti-tumor necrosis factor (TNF) biologic, which can lower the ability of your immune system to fight infections. Some people who received CIMZIA have developed serious infections, including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some of these serious infections have caused hospitalization and death. Your doctor should test you for TB before starting CIMZIA.

Stop using CIMZIA, and tell your doctor right away if you think you have an infection or have symptoms of an infection. Certain potentially fatal infections and cancers, including lymphoma, have occurred in people who received anti-TNF therapy.

For people who receive TNF blockers, including CIMZIA, the chances of getting certain types of cancers may increase. Some people who receive TNF blockers, including CIMZIA, have developed a rare type of cancer which may cause death, called hepatosplenic T-cell lymphoma. Some people who receive CIMZIA have developed certain types of skin cancer.

Other serious side effects
 
  • Heart failure, including new or worsening heart failure
  • Allergic reactions
  • Hepatitis B virus reactivation in people who carry the virus
  • New or worsening nervous system problems
  • Blood problems
  • Immune reactions, including a lupus-like syndrome

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.